Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Procrit Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Adagen Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Central Fill Pharmacy Automation Market Report 2026" has been added to ResearchAndMarkets.com's offering. The central fill pharmacy automation...
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Xgeva Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Neupogen (filgrastim) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's...
-
Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bi-specific monoclonal antibodies (mAbs) market is...
-
Brain Pacemaker Market grows with rising neurological disorders, DBS adoption, AI-enabled neurostimulation, and minimally invasive therapies.
-
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and...
-
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global...
-
1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous...